Detalhe da pesquisa
1.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 783-794, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381664
2.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 795-805, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962077
3.
Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
; 22(6): 1265-1274.e19, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354969
4.
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
Hepatology
; 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38117036
5.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Hepatology
; 77(1): 20-32, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35686937
6.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology
; 78(2): 397-415, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386786
7.
Recent Advances in the Management of Primary Sclerosing Cholangitis.
Clin Gastroenterol Hepatol
; 21(8): 2065-2075, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084929
8.
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Clin Gastroenterol Hepatol
; 21(7): 1902-1912.e13, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343847
9.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934287
10.
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
Gastroenterology
; 163(6): 1630-1642.e3, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150526
11.
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.
Am J Gastroenterol
; 118(2): 232-242, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729104
12.
The gut ecosystem and immune tolerance.
J Autoimmun
; 141: 103114, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748979
13.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
BMC Gastroenterol
; 23(1): 75, 2023 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922785
14.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
J Hepatol
; 77(2): 353-364, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367282
15.
Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies.
Clin Gastroenterol Hepatol
; 20(8): 1687-1700.e4, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474162
16.
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Hepatology
; 73(3): 1105-1116, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745270
17.
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Liver Int
; 42(1): 112-123, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34403559
18.
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA.
Dig Dis Sci
; 67(8): 4170-4180, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499271
19.
Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans.
Clin Immunol
; 230: 108825, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34403816
20.
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
Clin Gastroenterol Hepatol
; 19(6): 1248-1257, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707342